

Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Andrew Spencer,¹ Philippe Moreau,² Maria-Victoria Mateos,³ Hartmut Goldschmidt,⁴ Kenshi Suzuki,⁵ Mark-David Levin,⁶ Pieter Sonneveld,⁷ Robert Z. Orlowski,⁸ Sung-Soo Yoon,⁹ Saad Z. Usmani,¹⁰ Katja Weisel,¹¹ Donna Reece,¹² Tahamtan Ahmad,¹³ Huiling Pei,¹⁴ Wendy Garvin Mayo,¹⁵ Xue Gai,¹⁶ Jodi Carey,¹⁷ J. Blake Bartlett,¹⁵ Robin Carson,¹⁷ and Meletios A. Dimopoulos¹⁸

¹Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia; ²Hematology Department, University Hospital Hôtel-Dieu, Nantes, France; ³University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Centre for Cancer Research Institute of Cancer Molecular and Cellular Biology, Salamanca, Spain; ⁴University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases, Heidelberg, Germany; ⁵Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan; ⁶Albert Schweitzer Hospital, Dordrecht, The Netherlands; ⁷Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ⁸Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁹Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea; ¹⁰Memorial Sloan Kettering Cancer Center, New York, NY; ¹¹Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¹²Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada; ¹³Genmab US, Inc, Plainsboro, NJ; ¹⁴Janssen Research & Development, LLC, Titusville, NJ; ¹⁵Janssen Research & Development, LLC, Raritan, NJ; ¹⁶Janssen Research & Development, LLC, Beijing, China; ¹⁷Janssen Research & Development, LLC, Spring House, PA; and ¹⁸National and Kapodistrian University of Athens, Athens, Greece

Key Points

- Post hoc analyses of CASTOR/POLLUX showed PFS and depth of response benefit with daratumumab, regardless of relapse timing (early or late).
- These results support daratumumab use for patients with MM who relapse early after initial therapy and have functional high-risk disease.

High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS), regardless of cytogenetic risk, and achieved higher rates of complete response or better (\geq CR) and minimal residual disease (MRD) negativity vs that with Vd/Rd alone in relapsed/refractory MM. Post hoc analyses of CASTOR and POLLUX evaluated patient subgroups with 1 prior line of therapy based on timing of progression/relapse (early or late) after initiation of first line of therapy. PFS consistently favored the daratumumab-containing regimens across subgroups using both a 24- and 18-month early-relapse cutoff. In the CASTOR/POLLUX pooled data set, daratumumab reduced the risk of disease progression or death by 65% (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.26-0.48; $P < .0001$) in the early-relapse (<24 months) subgroup and by 65% (HR, 0.35; 95% CI, 0.26-0.47; $P < .0001$) in the late-relapse (\geq 24 months) subgroup. OS also favored the daratumumab-containing regimens in both the early-relapse (HR, 0.62; 95% CI, 0.45-0.86; $P = .0036$) and late-relapse (HR, 0.67; 95% CI, 0.48-0.93; $P = .0183$) subgroups in the pooled population using a 24-month cutoff. Rates of \geq CR and MRD negativity (10^{-5}) were higher with daratumumab vs control, regardless of progression/relapse timing. Although daratumumab is unable to fully overcome the adverse prognosis of early relapse, our results support the use of daratumumab for patients with 1 prior line of therapy, including for those who progress/relapse early after initial therapy and are considered to have functional high-risk MM. These trials were registered at www.clinicaltrials.gov as #NCT02136134 (CASTOR) and #NCT02076009 (POLLUX).

Submitted 27 April 2023; accepted 20 October 2023; prepublished online on *Blood Advances* First Edition 4 December 2023; final version published online 12 January 2024. <https://doi.org/10.1182/bloodadvances.2023010579>.

The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at <https://www.janssen.com/clinical-trials/transparency>.

Qualified researchers may request access through Yale Open Data Access Project site at <http://yoda.yale.edu>.

The full-text version of this article contains a data supplement.

© 2024 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Introduction

High-risk multiple myeloma (MM) is often defined based on the presence of cytogenetic abnormalities that have been associated with worse prognosis, namely t(4;14), t(14;16), t(14;20), gain(1q21)/amp(1q21), and/or del17p.^{1,2} However, patients with MM who relapse early after initial therapy, even in the absence of ≥ 1 of these features, are considered a functional high-risk group that is also associated with poor prognosis.^{1,3-6} A genomic analysis of patients with newly diagnosed MM (NDMM) in the Multiple Myeloma Research Foundation CoMMpass data set divided patients into 3 groups: a genomic high-risk group (defined as patients with t[4;14] or t[14;16] or complete loss of functional TP53 or 1q21 gain and International Staging System [ISS] stage III), a functional high-risk group (defined as patients with no markers of the genomic high-risk group but who were refractory to induction therapy or had early relapse within 12 months), and a standard-risk group (defined as patients who did not fulfill any of the criteria for genomic or functional high risk).⁴ Interestingly, patients in the functional high-risk group who had no clinically applied high-risk genetic factors had the poorest median overall survival (OS; 27.6 months) compared with those in the standard-risk group (median, not reached [NR]) or the genomic high-risk group (44.7 months).⁴ Patients with functional high-risk MM represent an ongoing unmet therapeutic need.

Daratumumab is a human immunoglobulin G κ monoclonal antibody targeting CD38 with a direct on-tumor⁷⁻¹⁰ and immunomodulatory¹¹⁻¹³ mechanism of action, demonstrating greater cytotoxicity toward MM cells *ex vivo* compared with analogs of other CD38 antibodies.¹⁴ Daratumumab induces higher levels of complement-dependent cytotoxicity and similar levels of antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis and, in the presence of Fc receptor crosslinking, which occurs naturally *in vivo*, daratumumab elicits similar levels of cell death compared with analogs of other CD38 antibodies.¹⁴ Results from phase 3 studies demonstrated that the addition of daratumumab to standard-of-care regimens improved progression-free survival (PFS) and OS and achieved deep and durable responses for patients with MM.¹⁵⁻²⁵ Daratumumab is approved as monotherapy for relapsed or refractory MM (RRMM) and in combination with standard-of-care regimens for patients with RRMM or NDMM.^{26,27}

In the phase 3 CASTOR and POLLUX studies, daratumumab in combination with bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd), respectively, improved PFS, regardless of cytogenetic risk status, and achieved higher rates of complete response or better (\geq CR) and minimal residual disease (MRD) negativity vs Vd or Rd alone for patients with RRMM.^{21,23} Recently reported survival data from CASTOR and POLLUX demonstrated, to our knowledge, for the first time, an OS benefit with daratumumab-containing regimens in RRMM, including for patients with high-risk cytogenetic abnormalities.^{22,24}

Here, we present post hoc analyses of CASTOR and POLLUX conducted to evaluate D-Vd vs Vd and D-Rd vs Rd in patient subgroups with 1 prior line of therapy based on timing of progression or relapse (early or late) after initiation of the first line of therapy to determine the efficacy of daratumumab-containing regimens in functional high-risk MM.

Methods

Trial design and oversight

CASTOR (NCT02136134) and POLLUX (NCT02076009) are multicenter, randomized, open-label, phase 3 studies in patients with RRMM. The study designs have been published previously.^{28,29} Briefly, eligible patients in both studies had received ≥ 1 prior line of therapy, achieved at least a partial response to ≥ 1 previous therapy, and documented progressive disease per International Myeloma Working Group criteria^{30,31} on or after their last regimen. Patients refractory to or intolerant of bortezomib or refractory to another proteasome inhibitor were excluded from CASTOR.²⁸ Patients refractory to or intolerant of lenalidomide were excluded from POLLUX.²⁹ Trial protocols were approved by independent ethics committees or institutional review boards at each site. Patients provided written informed consent, and both trials were conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.

Randomization and study treatment

Patients were randomly assigned 1:1 to D-Vd or Vd in CASTOR and to D-Rd or Rd in POLLUX.^{28,29} In CASTOR, patients were stratified based on ISS disease stage (I vs II vs III), number of prior lines of therapy (1 vs 2 or 3 vs >3), and previous bortezomib treatment (yes vs no). All patients received up to 8 cycles (21 days per cycle) of bortezomib (1.3 mg/m² subcutaneously on days 1, 4, 8, and 11) and dexamethasone (20 mg orally or IV on days 1, 2, 4, 5, 8, 9, 11, and 12). Patients in the D-Vd group received daratumumab (16 mg/kg IV) weekly in cycles 1 to 3, every 3 weeks in cycles 4 to 8, and every 4 weeks thereafter until disease progression or unacceptable toxicity.

In POLLUX, patients were stratified based on ISS disease stage (I vs II vs III), number of lines of previous therapy (1 vs 2 or 3 vs >3), and previous lenalidomide treatment (yes vs no). All patients received 28-day cycles of lenalidomide (25 mg orally on days 1-21 of each cycle; 10 mg if creatinine clearance was 30-60 mL/min) and dexamethasone (40 mg weekly) until disease progression or unacceptable toxicity. For patients in the D-Rd group, daratumumab (16 mg/kg IV) was administered weekly in cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks thereafter.

End points and assessments

In both studies, PFS was the primary end point and was defined as the duration from the date of randomization to the date of disease progression or death, whichever occurred first. Secondary end points included overall response rate (ORR), very good partial response or better (\geq VGPR) and MRD-negativity rates, and OS. Response and disease progression were assessed by a validated computer algorithm, based on International Myeloma Working Group criteria.^{30,31} MRD was assessed using bone marrow aspirate samples and evaluated via a next-generation sequencing approach using the clonoSEQ assay (version 2.0; Adaptive Biotechnologies, Seattle, WA). In this analysis, the early-relapse subgroup included patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included patients with 1 prior line of therapy who progressed or relapsed ≥ 24 months after initiating their first

line of therapy. In a second analysis, the early-relapse subgroup was defined as patients with 1 prior line of therapy who progressed or relapsed <18 months after initiating their first line of therapy; the late-relapse subgroup included patients with 1 prior line of therapy who progressed or relapsed \geq 18 months after initiating their first line of therapy.

Statistical analyses

Statistical methods have been published previously.^{21,23,28,29} Time-to-event end points were estimated using the Kaplan-Meier method. Hazard ratios (HRs), 95% confidence intervals (CIs), and *P* values were estimated using a Cox regression model, with treatment as the sole explanatory variable (stratified according to study ID for pooled analyses). ORRs and \geq VGPR and \geq CR rates were compared using the Cochran-Mantel-Haenszel test (stratified according to the study ID for pooled analyses). MRD-negativity rates were compared using Mantel-Haenszel estimate of the common odds ratio (stratified according to the study ID for pooled analyses), with the *P* value from a Fisher exact test. Data are presented for both the 24- and 18-month cutoffs defining early vs late relapse, respectively. Results have been pooled for CASTOR and POLLUX combined and are also presented for each study individually.

Results

Patients

A total of 240 and 290 patients from the pooled CASTOR/POLLUX data set were included in the early-relapse (<24 months) and late-relapse (\geq 24 months) subgroups, respectively. Patient baseline characteristics by relapse subgroup are summarized in Table 1. Baseline demographics and clinical characteristics for the pooled CASTOR/POLLUX data set using the 18-month early/late-relapse cutoff are shown in supplemental Table 1, and patient data for each individual study are shown in supplemental Table 2 (CASTOR) and supplemental Table 3 (POLLUX). Median time

from initiation of the prior line of therapy to progression/relapse was similar between treatment arms (D-Vd vs Vd; D-Rd vs Rd) within the early- and late-relapse groups for the 24-month and 18-month cutoffs (supplemental Table 4).

Efficacy

Median follow-up in the intent-to-treat population was 72.6 months (range, 0-79.8 months) for CASTOR and 79.7 months (range, 0-86.5 months) for POLLUX. In the CASTOR/POLLUX pooled population, median PFS with daratumumab vs control was 27.9 vs 10.0 months (HR, 0.35; 95% CI, 0.26-0.48; *P* < .0001) in the early-relapse subgroup (<24 months) and 51.8 vs 14.4 months (HR, 0.35; 95% CI, 0.26-0.47; *P* < .0001) in the late-relapse subgroup (\geq 24 months; Figure 1A). Similar PFS benefit with daratumumab vs control was observed when an 18-month cutoff was used. Median PFS with daratumumab vs control was 26.2 vs 10.3 months (HR, 0.44; 95% CI, 0.30-0.64; *P* < .0001) in the early-relapse subgroup (<18 months) and 43.7 vs 11.8 months (HR, 0.32; 95% CI, 0.25-0.42; *P* < .0001) in the late-relapse subgroup (\geq 18 months; supplemental Figure 1A). In the CASTOR/POLLUX pooled data set, the median OS with daratumumab vs control was 65.0 vs 38.2 months (HR, 0.62; 95% CI, 0.45-0.86; *P* = .0036) in the early-relapse subgroup (<24 months) and NR vs 67.3 months (HR, 0.67; 95% CI, 0.48-0.93; *P* = .0183) in the late-relapse subgroup (\geq 24 months; Figure 1B). OS benefit with daratumumab vs control was also observed in the early-relapse (median OS: 47.0 vs 38.6 months, respectively; HR, 0.77; 95% CI, 0.52-1.14; *P* = .1839) and late-relapse (median OS: NR vs 59.1 months, respectively; HR, 0.59; 95% CI, 0.44-0.79; *P* = .0003) subgroups using the 18-month early-relapse cutoff (supplemental Figure 1B).

In the pooled CASTOR/POLLUX population, \geq CR rates were higher with daratumumab vs control in the early-relapse (<24 months; 46.3% vs 13.6%; *P* < .0001) and late-relapse (\geq 24 months; 57.2% vs 29.8%; *P* < .0001) subgroups (Table 2). Rates of \geq VGPR were also higher with daratumumab vs

Table 1. Baseline demographic and clinical characteristics according to the relapse subgroup

	Early relapse (<24 mos)		Late relapse (\geq 24 mos)	
	DARA (n = 125)	Control (n = 115)	DARA (n = 146)	Control (n = 144)
Age, y				
Median (range)	65 (30-89)	65 (40-85)	64 (34-84)	64 (42-85)
\geq 75 y, n (%)	17 (13.6)	17 (14.8)	8 (5.5)	16 (11.1)
ISS staging, n (%)*				
I	62 (49.6)	51 (44.3)	73 (50.0)	81 (56.3)
II	45 (36.0)	43 (37.4)	45 (30.8)	42 (29.2)
III	18 (14.4)	21 (18.3)	28 (19.2)	21 (14.6)
Cytogenetic risk, n (%)†	(n = 93)	(n = 93)	(n = 116)	(n = 96)
Standard	72 (77.4)	72 (77.4)	94 (81.0)	85 (88.5)
High	21 (22.6)	21 (22.6)	22 (19.0)	11 (11.5)

Data shown of the pooled CASTOR and POLLUX data set.

The early-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed \geq 24 months after initiating their first line of therapy.

DARA, daratumumab; ITT, intent-to-treat.

*ISS staging was based on the combination of serum β_2 -microglobulin and albumin.

†Cytogenetic risk was assessed locally by fluorescence in situ hybridization or karyotype testing; high risk was defined as the presence of t(4;14), t(14;16), or del17p.




Figure 1.

Table 2. Response rates and MRD-negativity rates according to the relapse subgroup

	Early relapse (<24 mos)			Late relapse (≥24 mos)		
	DARA	Control	P	DARA	Control	P
Response, n (%)*						
Patients evaluated, n	121	110		145	141	
ORR	110 (90.9)	81 (73.6)	.0004†	136 (93.8)	114 (80.9)	.0010‡
≥CR	56 (46.3)	15 (13.6)	<.0001†	83 (57.2)	42 (29.8)	<.0001†
sCR	20 (16.5)	2 (1.8)		44 (30.3)	21 (14.9)	
CR	36 (29.8)	13 (11.8)		39 (26.9)	21 (14.9)	
≥VGPR	94 (77.7)	43 (39.1)	<.0001†	114 (78.6)	83 (58.9)	.0003†
VGPR	38 (31.4)	28 (25.5)		31 (21.4)	41 (29.1)	
PR	16 (13.2)	38 (34.5)		22 (15.2)	31 (22.0)	
MR	3 (2.5)	10 (9.1)		2 (1.4)	7 (5.0)	
SD	4 (3.3)	15 (13.6)		6 (4.1)	18 (12.8)	
PD	4 (3.3)	3 (2.7)		0	2 (1.4)	
NE	0	1 (0.9)		1 (0.7)	0	
MRD (10⁻⁵) ‡						
Patients evaluated, n	125	115		146	144	
MRD negative, n (%)	28 (22.4)	3 (2.6)	<.0001§	46 (31.5)	15 (10.4)	<.0001§

Data shown of the pooled CASTOR and POLLUX data set.

The early-relapse subgroup included patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included patients with 1 prior line of therapy who progressed or relapsed ≥24 months after initiating their first line of therapy.

DARA, daratumumab; ITT, intent-to-treat; MR, minimal response; NE, not evaluable; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable disease.

*Response-evaluable population with 1 prior line of therapy. The response-evaluable population was defined as patients with a confirmed diagnosis of MM and measurable disease at the baseline or screening visit who received ≥1 administration of study treatment and had ≥1 postbaseline disease assessment.

†P value was calculated using the Cochran-Mantel-Haenszel χ^2 test stratified based on study ID.

‡ITT population with 1 prior line of therapy.

§P value was calculated using the Fisher exact test.

control in the early-relapse (77.7% vs 39.1%; $P < .0001$) and late-relapse (78.6% vs 58.9%; $P = .0003$) subgroups. MRD-negativity rates (10⁻⁵ sensitivity) were higher with daratumumab vs control, regardless of relapse timing (early [<24 months], 22.4% vs 2.6% [$P < .0001$]; late [≥24 months], 31.5% vs 10.4% [$P < .0001$]; Table 2). Rates of ≥CR, ≥VGPR, and MRD negativity (10⁻⁵ sensitivity) were also higher with daratumumab vs control in the early-relapse and late-relapse subgroups when the 18-month cutoff was used to define early relapse (supplemental Table 5).

In the CASTOR study, median PFS with D-Vd vs Vd was 21.2 vs 7.3 months (HR, 0.32; 95% CI, 0.19-0.54; $P < .0001$) in the early-relapse subgroup (<24 months), and 33.2 vs 8.0 months (HR, 0.20; 95% CI, 0.13-0.30; $P < .0001$) in the late-relapse subgroup (≥24 months; Figure 2). Rates of ≥CR, ≥VGPR, and MRD negativity (10⁻⁵ sensitivity) were higher with D-Vd vs Vd in both the early-relapse (<24 months) and late-relapse (≥24 months) subgroups (Table 3). The efficacy with D-Vd vs Vd using the 18-month early-relapse cutoff was generally similar to that observed using the 24-month early-relapse cutoff (supplemental Figure 2; supplemental Table 6).

In the POLLUX study, the median PFS with D-Rd vs Rd was 43.7 vs 11.8 months (HR, 0.37; 95% CI, 0.25-0.55; $P < .0001$) in the early-relapse subgroup (<24 months) and 66.0 vs 35.5 months (HR, 0.64; 95% CI, 0.42-0.97; $P = .0351$) in the late-relapse subgroup (≥24 months; Figure 3). Rates of ≥CR, ≥VGPR, and MRD negativity (10⁻⁵ sensitivity) were higher with D-Rd vs Rd in both the early-relapse (<24 months) and late-relapse (≥24 months) subgroups (Table 3). Efficacy with D-Rd vs Rd using the 18-month early-relapse cutoff was generally consistent with that observed using the 24-month early-relapse cutoff (supplemental Figure 3; supplemental Table 6).

Discussion

Functional high-risk MM is becoming an increasingly more recognized subgroup of MM that is associated with poor outcomes. In a retrospective study of patients with MM treated with novel therapies (immunomodulatory drugs and proteasome inhibitors) at the Mayo Clinic between 2006 and 2014, the median OS was significantly shorter for patients with early relapse (within 12 months of starting initial therapy) vs for those with late relapse

Figure 1. Pooled progression free and overall survival based on the 24 month cut-off. PFS (A) and OS (B) according to the relapse subgroup (<24 and ≥24 months) in the pooled CASTOR/POLLUX population. Kaplan-Meier plots of PFS and OS in patients with 1 prior line of therapy who progressed or relapsed early or late after initiation of first line of therapy. The early-relapse subgroup included intent-to-treat (ITT) patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed ≥24 months after initiating their first line of therapy. DARA, daratumumab.




Figure 2. PFS by relapse subgroup (<24 and ≥24 months) in CASTOR. Kaplan-Meier plot of PFS in patients with 1 prior line of therapy who progressed or relapsed early or late after initiation of first line of therapy. The early-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed ≥24 months after initiating their first line of therapy.

(21.0 months vs NR; $P < .001$).³ Outcomes were also evaluated in patients with early relapse after early autologous stem cell transplant (ASCT); the median OS from ASCT for patients relapsing within 12 months was 23.1 months compared with 122.2 months for the remaining patients ($P < .001$).³ Similarly, real-world data from a myeloma registry showed that median OS was markedly inferior for patients with early progression (within 12 months of commencing firstline therapy) vs those without early progression (20.2 vs 60.7 months; $P < .001$).⁵ These data highlight the need for effective therapies for this subgroup of patients with functional high-risk MM who relapse early after initial therapy.

Considering the poor prognosis of patients with functional high-risk MM, early identification of patients at risk of early relapse is crucial. In this post hoc analysis, few patients in the early-relapse subgroup (<24 months; Table 1) presented with high-risk cytogenetic factors (daratumumab, 22.6%; control, 22.6%) or ISS stage III disease (daratumumab, 14.4%; control, 18.3%). Because only a subset of patients receive a second line of therapy and qualify for a clinical study, these patients may reflect the subgroup with higher risk disease. These results support the need for a broader definition of high-risk disease or stratification based on functional high-risk status in future studies.

This post hoc analysis evaluated the efficacy of daratumumab-containing regimens in the CASTOR and POLLUX studies in patient subgroups based on timing of progression or relapse

(early or late) after initiation of the first line of therapy. Because of the limited number of patients who relapsed before 12 months, early relapse for this analysis was defined as patients with 1 prior line of therapy who progressed or relapsed <24 months (primary analysis) or <18 months (secondary analysis) after initiating their first line of therapy. Extending the cutoff for the early-relapse definition from <18 months to <24 months increases the sample size of the early-relapse group, providing greater statistical power to show differentiation between treatment groups. At a median follow-up of >6 years, PFS consistently favored the daratumumab-containing regimens across both the early- and late-relapse subgroups (24-month and 18-month cutoffs) in the pooled CASTOR/POLLUX population and for each study individually. In the CASTOR/POLLUX pooled data set, daratumumab reduced the risk of disease progression or death by 65% (HR, 0.35; 95% CI, 0.26-0.48; $P < .0001$) in the early-relapse (<24 months) subgroup and by 65% (HR, 0.35; 95% CI, 0.26-0.47; $P < .0001$) in the late-relapse (≥24 months) subgroup. Interestingly, the PFS benefit with daratumumab vs control was similar between the early- and late-relapse subgroups for the pooled analysis but was more pronounced with D-Vd vs Vd in the late-relapse subgroup in CASTOR and more pronounced with D-Rd vs Rd in the early-relapse subgroup in POLLUX. Small patient subgroups, particularly the CASTOR early-relapse subgroups, may limit the interpretation of results.

Table 3. Response rates and MRD-negativity rates according to the relapse subgroup in CASTOR and POLLUX

	CASTOR					
	Early relapse (<24 mos)			Late relapse (≥24 mos)		
	D-Vd	Vd	P	D-Vd	Vd	P
Response, n (%)*						
Patients evaluated, n	47	36		72	73	
ORR	39 (83.0)	26 (72.2)	.2415†	70 (97.2)	55 (75.3)	.0001†
≥CR	13 (27.7)	4 (11.1)	.0657†	39 (54.2)	12 (16.4)	<.0001†
sCR	2 (4.3)	0		16 (22.2)	5 (6.8)	
CR	11 (23.4)	4 (11.1)		23 (31.9)	7 (9.6)	
≥VGPR	31 (66.0)	12 (33.3)	.0034†	60 (83.3)	34 (46.6)	<.0001†
VGPR	18 (38.3)	8 (22.2)		21 (29.2)	22 (30.1)	
PR	8 (17.0)	14 (38.9)		10 (13.9)	21 (28.8)	
MR	2 (4.3)	2 (5.6)		1 (1.4)	6 (8.2)	
SD	2 (4.3)	7 (19.4)		1 (1.4)	10 (13.7)	
PD	4 (8.5)	1 (2.8)		0	2 (2.7)	
NE	0	0		0	0	
MRD (10⁻⁵)‡						
Patients evaluated, n	50	38		72	75	
MRD negative, n (%)	5 (10.0)	0	.0669§	20 (27.8)	3 (4.0)	<.0001§
	POLLUX					
	Early relapse (<24 mos)			Late relapse (≥24 mos)		
	D-Rd	Rd	P	D-Rd	Rd	P
Response, n (%)*						
Patients evaluated, n	74	74		73	68	
ORR	71 (95.9)	55 (74.3)	.0002†	66 (90.4)	59 (86.8)	.4967†
≥CR	43 (58.1)	11 (14.9)	<.0001†	44 (60.3)	30 (44.1)	.0558†
sCR	18 (24.3)	2 (2.7)		28 (38.4)	16 (23.5)	
CR	25 (33.8)	9 (12.2)		16 (21.9)	14 (20.6)	
≥VGPR	63 (85.1)	31 (41.9)	<.0001‡	54 (74.0)	49 (72.1)	.7987‡
VGPR	20 (27.0)	20 (27.0)		10 (13.7)	19 (27.9)	
PR	8 (10.8)	24 (32.4)		12 (16.4)	10 (14.7)	
MR	1 (1.4)	8 (10.8)		1 (1.4)	1 (1.5)	
SD	2 (2.7)	8 (10.8)		5 (6.8)	8 (11.8)	
PD	0	2 (2.7)		0	0	
NE	0	1 (1.4)		1 (1.4)	0	
MRD (10⁻⁵)‡						
Patients evaluated, n	75	77		74	69	
MRD negative, n (%)	23 (30.7)	3 (3.9)	<.0001§	26 (35.1)	12 (17.4)	.0225§

The early-relapse subgroup included patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included patients with 1 prior line of therapy who progressed or relapsed ≥24 months after initiating their first line of therapy.

ITT, intent-to-treat; MR, minimal response; NE, not evaluable; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable disease.

*Response-evaluable population with 1 prior line of therapy. The response-evaluable population was defined as patients with a confirmed diagnosis of MM and measurable disease at the baseline or screening visit who received ≥1 administration of study treatment and had ≥1 postbaseline disease assessment.

†P value was calculated using the Cochran-Mantel-Haenszel χ^2 test.

‡ITT population with 1 prior line of therapy.

§P value was calculated using the Fisher exact test.

In the pooled analysis and for CASTOR and POLLUX alone, rates of ≥CR and MRD negativity were higher with the daratumumab-containing regimens vs control, regardless of relapse timing. OS favored the daratumumab-containing regimens in both the early

and late-relapse subgroups in the pooled CASTOR/POLLUX population using the 24-month cutoff to define early progression or relapse; however, the difference in OS was not as pronounced between daratumumab and control for the early-relapse subgroup




Figure 3. PFS by relapse subgroup (<24 and ≥24 months) in POLLUX. Kaplan-Meier plot of PFS in patients with 1 prior line of therapy who progressed or relapsed early or late after initiation of first line of therapy. The early-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed ≥24 months after initiating their first line of therapy.

defined using the 18-month cutoff. Significant challenges are associated with the interpretation of OS data from this subgroup analysis and should be considered. There was low statistical power for OS analyses after dividing patients into small subgroups because of the relatively low number of OS events overall in each study. Therefore, OS data for the early-relapse and late-relapse subgroups are only reported for the CASTOR/POLLUX pooled population and not for each study individually.

A similar subgroup analysis of the phase 3 CANDOR study of daratumumab plus carfilzomib and dexamethasone (D-Kd) vs Kd alone for patients with RRMM based on the timing of relapse (early vs late) was previously conducted.³² Among patients in CANDOR who had received 1 prior line of therapy, ORR and ≥CR rates were higher in the D-Kd group than in the Kd group, regardless of relapse status (with early relapse defined as relapse <18 months after the first line of therapy), and PFS results also favored the D-Kd group, regardless of relapse status.³² A subgroup analysis of the phase 3 IKEMA study of isatuximab plus Kd (Isa-Kd) vs Kd alone was conducted for patients with RRMM who experienced early vs late relapse, with early relapse defined as relapse <12 months from initiation of the most recent line of therapy for patients with ≥2 prior lines, relapse <18 months for patients with 1 prior line, or relapse <12 months from ASCT.³³ In patients with either early or late relapse, Isa-Kd improved PFS and depth of response vs Kd alone. Two multicohort phase 2 studies are also evaluating chimeric antigen receptor T-cell therapy for patients with MM and early

relapse after initial therapy. In cohort B of the phase 2 CARTITUDE-2 study, patients with 1 prior line of therapy (including a proteasome inhibitor and immunomodulatory drug) who had early progression (≤12 months after ASCT or ≤12 months after start of antimyeloma therapy for patients who did not undergo ASCT) achieved deep and durable responses with ciltacabtagene autoleucel, with an 18-month PFS rate of 83%.³⁴ In cohort 2a of the phase 2 KarMMa-2 study, idecabtagene vicleucel demonstrated frequent, deep responses and a median PFS of 11.4 months in patients with MM who experienced early relapse, defined as disease progression within 18 months of initiation of frontline treatment that included induction, ASCT, and lenalidomide-based maintenance therapy.³⁵

Because many of the patients in CASTOR and POLLUX likely received a proteasome inhibitor for a fixed duration as part of their frontline therapy, patients who progressed or relapsed within the shorter time frame (<18 months) were more likely to exhibit some degree of proteasome inhibitor resistance than those who progressed or relapsed within the longer time frame (<24 months). Although the sample size was small for the early-relapse (<18 months) subgroup, the data from our analyses may suggest that, for patients who progressed or relapsed earlier (sooner after prior bortezomib exposure), secondline D-Rd may be the preferred treatment option for selected patients. Results from a secondary analysis of the ALLG MM21 study showed that patients with NDMM who were eligible for transplantation with suboptimal

response or primary refractoriness to bortezomib induction who were switched to pre-ASCT D-Rd induction followed by post-ASCT D-Rd consolidation achieved substantial disease control.³⁶ Furthermore, our finding that PFS with Vd was similar for patients with early relapse and late relapse further supports the possible role of proteasome inhibitor resistance and could be interpreted to indicate that Vd is not an appropriate secondline therapy for many patients in this setting. Thus, the data from our post hoc analyses could have implications on subsequent treatment selection based on the timing of progression or relapse.

Clinical data show that receipt of frontline daratumumab is important to maximize the duration of response to treatment. Results from the phase 3 ALCYONE and MAIA studies demonstrate significantly prolonged OS and PFS with the addition of daratumumab to standard-of-care regimens vs standard of care alone for transplant-ineligible patients with NDMM.^{18,20} Patients who do not receive frontline daratumumab and relapse after initial therapy can be salvaged with daratumumab-based regimens. As discussed, in CASTOR and POLLUX, D-Vd or D-Rd prolonged PFS, regardless of cytogenetic risk, and achieved higher rates of \geq CR and MRD negativity vs Vd or Rd alone for patients with RRMM.^{21,23} In CASTOR, the most pronounced PFS and OS benefit with D-Vd vs Vd was in patients with 1 prior line of therapy.^{21,22} In POLLUX, when analyzed based on the number of prior lines of therapy, patients with 1 prior line of therapy had the longest median PFS and OS.^{23,24} Moreover, with extended follow-up, no new safety concerns outside of the known safety profile of daratumumab have been observed.²¹⁻²⁴

The current post hoc subgroup analyses showed PFS, OS, and depth of response benefits of daratumumab-containing regimens for patients with 1 prior line of therapy, regardless of progression/relapse timing (early or late), supporting the use of D-Vd and D-Rd for patients with RRMM, including those considered to have functional high-risk disease. However, even with the addition of daratumumab, patients with early relapse still have inferior outcomes compared with those who experience late relapse, which may provide rationale to add other agents to D-Vd or D-Rd using daratumumab as a backbone to further improve patient outcomes. It is also important to note that many patients with MM may not receive secondline therapy^{37,38} and that waiting until progression or relapse (whether early or late) to use daratumumab may not always lead to a significant survival benefit.

In summary, patients with functional high-risk MM who relapse early after initial therapy have poor outcomes, representing an unmet therapeutic need. At a median follow-up of >6 years, the results from these post hoc analyses showed PFS and depth of response benefits of daratumumab-containing regimens vs control for patients with 1 prior line of therapy, regardless of progression/relapse timing (early or late). Moreover, OS favored the daratumumab-containing regimens in both the early and late-relapse subgroups in the pooled CASTOR/POLLUX population. These results, combined with previous subgroup analyses of CASTOR and POLLUX,^{21,23} show that daratumumab-containing regimens maintain consistent clinical benefits for patients with high-risk RRMM, as defined either by cytogenetics or by early progression/relapse. Although daratumumab is unable to fully overcome the adverse prognosis of early relapse, our results support the use of D-Vd and D-Rd for patients with RRMM and 1 prior line of therapy, including for patients who

progress or relapse early after initial therapy and are considered to have functional high-risk disease.

Acknowledgments

The authors thank the patients who participated in the CASTOR and POLLUX studies and their families as well as the study coinvestigators, research nurses, and coordinators at each of the clinical sites. Medical writing and editorial support were provided by Lisa Shannon of Lumanity Communications Inc and were funded by Janssen Global Services, LLC.

These studies (NCT02136134 and NCT02076009) were sponsored by Janssen Research & Development, LLC.

Authorship

Contribution: All authors participated in the conception and design of the study or in the acquisition, analysis, or interpretation of the data and in drafting, revising, and approving the final version of the manuscript before submission.

Conflict-of-interest disclosure: A.S. served on an advisory board for AbbVie, Amgen, Antegene, Bristol Myers Squibb, HaemaLogiX, Janssen, Pfizer, Roche, and Secura Bio; served on a speakers bureau for Bristol Myers Squibb and Janssen; received research support from AbbVie, Amgen, Bristol Myers Squibb, HaemaLogiX, Janssen, and PharmaMar; and received honoraria from AbbVie, Amgen, Antegene, Bristol Myers Squibb, HaemaLogiX, Janssen, Pfizer, Roche, and Secura Bio. P.M. served in a consulting or advisory role for Celgene, Janssen, Amgen, GlaxoSmithKline, Sanofi, AbbVie, Oncopptides, and Roche; and received honoraria from Celgene, Janssen-Cilag, Amgen, GlaxoSmithKline, AbbVie, Sanofi, Oncopptides, and Roche. M.-V.M. served in a consulting or advisory role for Takeda, Janssen-Cilag, Celgene, Amgen, AbbVie, GlaxoSmithKline, Pfizer, Regeneron, and Roche/Genentech, and received honoraria from Janssen-Cilag, Celgene, Amgen, Takeda, GlaxoSmithKline, AbbVie/Genentech, and Sanofi. H.G. received grants and/or provision of an investigational medicinal product from Amgen, Bristol Myers Squibb, Celgene, Chugai, Dietmar Hopp Foundation, Janssen, Johns Hopkins University, and Sanofi; received research support from Amgen, Bristol Myers Squibb, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp & Dohme, Sanofi, Mundipharma GmbH, Takeda, and Novartis; served on advisory boards for Adaptive Biotechnology, Amgen, Bristol Myers Squibb, Celgene, Janssen, Sanofi, and Takeda; and received honoraria from Amgen, Bristol Myers Squibb, Celgene, Chugai, GlaxoSmithKline, Janssen, Novartis, and Sanofi. K.S. received honoraria from Celgene, Takeda, Ono Pharmaceutical, Amgen, Novartis, Sanofi, Bristol Myers Squibb, AbbVie, and Janssen; served in a consulting or advisory role for Amgen, Janssen, Takeda, and Celgene; and received research funding from Bristol Myers Squibb and Celgene. M.-D.L. received travel support from Takeda and Janssen, and received honoraria from AbbVie, Celgene, Janssen, and Takeda. P.S. received research support from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, and Takeda, and received honoraria from and served on an advisory board for Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm, SkylineDx, and Takeda. R.Z.O. served on advisory committees for and received honoraria from AbbVie, Amgen, AstraZeneca, Biotheryx, Bristol Myers Squibb, Celgene, EcoR1 Capital, Forma Therapeutics, Genzyme, GlaxoSmithKline, Ionis

Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm, Kite Pharma, Legend Biotech, Meridian Therapeutics, Monte Rosa Therapeutics, Molecular Partners, Neoleukin Therapeutics, Oncopeptides, Regeneron, Sanofi-Aventis, Servier, and Takeda; and received research funding from Asyila Therapeutics, Inc, Biotheryx, CARsgen Therapeutics, Celgene, Exelixis, Janssen, Sanofi-Aventis, and Takeda. S.-S.Y. received honoraria from Novartis; served on advisory boards for Amgen, Antengene, Astellas, Celgene, Janssen, Novartis, and Takeda; and received research funding from Kyowa Hakko Kirin, Roche-Genentech, and Yuhan Pharma. S.Z.U. received research funding from Amgen, Array BioPharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDx, and Takeda; served in a consulting role for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Edo Pharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, SkylineDx, Takeda, and TeneoBio; and served as a speaker for Amgen, Bristol Myers Squibb, Janssen, and Sanofi. K.W. received research support from Amgen, Bristol Myers Squibb/Celgene, Janssen, and Sanofi; received honoraria from AbbVie, Adaptive Biotech, Amgen, AstraZeneca, Bristol Myers Squibb/Celgene, BeiGene, GlaxoSmithKline, Janssen, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, and Takeda; and received consulting fees from AbbVie, Adaptive Biotech, Amgen,

Bristol Myers Squibb/Celgene, BeiGene, Janssen, GlaxoSmithKline, Karyopharm, Oncopeptides, Pfizer, Roche, Sanofi, and Takeda. D.R. received honoraria from Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, and Takeda; served in a consulting or advisory role for Amgen, Bristol Myers Squibb/Celgene, Janssen, Karyopharm, and Takeda; received research funding from Bristol Myers Squibb/Celgene, Janssen, Millennium, and Takeda; provided expert testimony for Bristol Myers Squibb/Celgene and Janssen; and serves as the voluntary chief medical officer of the Canadian Myeloma Research Network. T.A. is an employee of and owns stock and options in Genmab. H.P., X.G., and J.C. are employees of Janssen and own stock in Johnson & Johnson. W.G.M. and R.C. are employees of Janssen. M.A.D. received honoraria from Amgen, BeiGene, Bristol Myers Squibb, Janssen, and Takeda. J.B.B. declares no competing financial interests.

ORCID profiles: M.-V.M., [0000-0003-2390-1218](https://orcid.org/0000-0003-2390-1218); H.G., [0000-0003-0961-0035](https://orcid.org/0000-0003-0961-0035); K.S., [0000-0001-7132-5337](https://orcid.org/0000-0001-7132-5337); P.S., [0000-0002-0808-2237](https://orcid.org/0000-0002-0808-2237); S.-S.Y., [0000-0003-2591-7459](https://orcid.org/0000-0003-2591-7459).

Correspondence: Andrew Spencer, Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, 55 Commercial Rd, Melbourne, VIC 3004, Australia; email: andrew.spencer@monash.edu.

References

- Costa LJ, Usmani SZ. Defining and managing high-risk multiple myeloma: current concepts. *J Natl Compr Canc Netw*. 2020;18(12):1730-1737.
- Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2022;97(8):1086-1107.
- Majithia N, Rajkumar SV, Lacy MQ, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. *Leukemia*. 2016;30(11):2208-2213.
- Soekhojo CY, Chung TH, Furqan MS, Chng WJ. Genomic characterization of functional high-risk multiple myeloma patients. *Blood Cancer J*. 2022;12(1):24.
- Spencer A, Mollee P, Blacklock HA, et al. Real-world outcome for newly diagnosed patients with functional high-risk myeloma – a Myeloma and Related Diseases Registry analysis. *Blood*. 2019;134(suppl 1):269.
- Belli AJ, Hansen E, Kansagra A, Dilwali K, Wang CK. Real-world treatment patterns and outcomes of patients with functional high-risk (early relapse) multiple myeloma. *Blood*. 2020;136(suppl 1):17-18.
- de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J Immunol*. 2011;186(3):1840-1848.
- Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. *Blood*. 2014;124(21):3474.
- Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. *MAbs*. 2015;7(2):311-321.
- Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. *J Immunol*. 2016;197(3):807-813.
- Krejci J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38⁺ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. *Blood*. 2016;128(3):384-394.
- Adams HC III, Stevensnaert F, Krejci J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. *Cytometry A*. 2019;95(3):279-289.
- Casneuf T, Adams HC III, van de Donk NWCJ, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. *Leukemia*. 2021;35(2):573-584.
- Kinder M, Bahlis NJ, Malavasi F, et al. Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. *Haematologica*. 2021;106(7):2004-2008.
- Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*. 2019;394(10192):29-38.

16. Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021;22(10):1378-1390.
17. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med.* 2018; 378(6):518-528.
18. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet.* 2020;395(10218):132-141.
19. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. *N Engl J Med.* 2019;380(22): 2104-2115.
20. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22(11):1582-1596.
21. Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. *Clin Lymphoma Myeloma Leuk.* 2020;20(8):509-518.
22. Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. *J Clin Oncol.* 2023;41(8):1600-1609.
23. Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. *Leukemia.* 2020;34(7):1875-1884.
24. Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. *J Clin Oncol.* 2023;41(8):1590-1599.
25. Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021;22(6):801-812.
26. DARZALEX (daratumumab) injection. Package insert. Janssen Biotech, Inc; 2022.
27. European Medicines Agency. DARZALEX 20 mg/mL concentrate for solution for infusion [summary of product characteristics]. Accessed 11 October 2022. https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf
28. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med.* 2016;375(8): 754-766.
29. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med.* 2016;375(14): 1319-1331.
30. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. *Leukemia.* 2006;20(9):1467-1473.
31. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood.* 2011;117(18):4691-4695.
32. Weisel K, Geils G, Karlin L, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of the phase 3 CANDOR study in patients with early or late relapse. Poster presented at: 62nd American Society of Hematology annual meeting and exposition; 5-8 December 2020; Virtual.
33. Facon T, Moreau P, Baker R, et al. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. Oral presentation at: 64th American Society of Hematology annual meeting and exposition; 10-13 December 2022; New Orleans, LA.
34. van de Donk NWCJ, Agha M, Cohen AD, et al. Ciltacabtagene autoleucl (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 cohort B 18-month follow-up. Poster presented at: 64th American Society of Hematology annual meeting and exposition; 10-13 December 2022; New Orleans, LA.
35. Usmani S, Patel K, Hari P, et al. KarMMA-2 cohort 2a: efficacy and safety of idecabtagene vicleucl in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Oral presentation at: 64th American Society of Hematology annual meeting and exposition; 10-13 December 2022; New Orleans, LA.
36. Lim S-I, Reynolds J, Quach H, et al. Secondary analysis of the MM21 trial: response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients failing front-line bortezomib-based induction therapy. Poster presented at: 64th American Society of Hematology annual meeting and exposition; 10-13 December 2022; New Orleans, LA.
37. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. *Br J Haematol.* 2016;175(2):252-264.
38. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer.* 2020;20(1):1087.